Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.92 (market cap $2.03B). The key difference: Direxion Daily 20 Year Treasury Bull 3X Shares is far larger — about 149× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 12,241,664). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| CTXR | TMF | |
|---|---|---|
Market Cap | $13.62M | $2.03B |
Volume | 132,438 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $44.14 |
52-Week Low | $0.48 | $25.19 |
Typical Hold Time | 17 Days | 28 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.93, up 2.75% with elevated volume. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF saw increased trading interest recently, with support at $25 and resistance at $26.
As a leveraged ETF tracking long-term Treasuries, TMF's outlook hinges on interest rate trends. Opportunities exist if rates fall, but risks include rate hikes and volatility decay. Investors should monitor Fed policy for directional cues amid current bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
